MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- DR. REDDY'S LABORATORIES LIMITED (pharmaceuticals)
- DR. REDDY'S LABORATORIES LIMITED Financial Data
Dr. Reddys Fact Sheet 
(REDY)
Here is the latest financial fact sheet of Dr. Reddys. For more details, see the Dr. Reddys quarterly results and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.
DR. REDDYS LAB Price History
| % ch | % | 1.5 |
| No. of shares | m | 165.71 |
| % ch week | % | 1.9 |
| % ch 1-mth | % | 1.6 |
| % ch 12-mth | % | 6.0 |
| 52 week H/L | Rs | 2,745.0/1,888.0 |
DR. REDDYS LAB Financials
| No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| DR. REDDYS LAB EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 2,940 | 3,662 | 4,383 | 3,397 | 2,788 | |
| Low | Rs | 1,766 | 2,250 | 2,750 | 2,560 | 1,902 | |
| Sales per share (Unadj.) | Rs | 788.6 | 881.8 | 912.5 | 856.5 | 860.8 | |
| Earnings per share (Unadj.) | Rs | 115.4 | 137.1 | 124.9 | 78.0 | 57.1 | |
| Diluted earnings per share | Rs | 118.5 | 141.0 | 128.6 | 78.0 | 57.1 | |
| Cash flow per share (Unadj.) | Rs | 153.5 | 181.7 | 179.9 | 139.9 | 122.0 | |
| Dividends per share (Unadj.) | Rs | 18.00 | 20.00 | 20.00 | 20.00 | 20.00 | |
| Adj. dividends per share | Rs | 18.48 | 20.56 | 20.59 | 20.00 | 20.02 | |
| Dividend yield (eoy) | % | 0.8 | 0.7 | 0.6 | 0.7 | 0.9 | |
| Book value per share (Unadj.) | Rs | 462.4 | 635.8 | 736.8 | 739.8 | 757.7 | |
| Adj. book value per share | Rs | 474.6 | 653.8 | 758.5 | 740.0 | 758.7 | |
| Shares outstanding (eoy) | m | 170.11 | 170.38 | 170.61 | 165.74 | 165.91 | |
| Bonus/Rights/Conversions | ESOP | ESOP | ESOP | BB | ESOP | ||
| Price / Sales ratio | x | 3.0 | 3.4 | 3.9 | 3.5 | 2.7 | |
| Avg P/E ratio | x | 20.4 | 21.6 | 28.6 | 38.2 | 41.1 | |
| P/CF ratio (eoy) | x | 15.3 | 16.3 | 19.8 | 21.3 | 19.2 | |
| Price / Book Value ratio | x | 5.1 | 4.6 | 4.8 | 4.0 | 3.1 | |
| Dividend payout | % | 15.6 | 14.6 | 16.0 | 25.7 | 35.0 | |
| Avg Mkt Cap | Rs m | 400,277 | 503,643 | 608,481 | 493,632 | 389,034 | |
| No. of employees | `000 | 19.0 | 19.9 | 21.7 | 22.7 | 23.5 | |
| Total wages/salary | Rs m | 24,754 | 29,446 | 31,174 | 31,068 | 32,149 | |
| Avg. sales/employee | Rs Th | 7,060.7 | 7,565.7 | 7,184.6 | 6,259.0 | 6,070.8 | |
| Avg. wages/employee | Rs Th | 1,302.8 | 1,482.9 | 1,438.6 | 1,369.8 | 1,366.6 | |
| Avg. net profit/employee | Rs Th | 1,033.3 | 1,176.6 | 983.2 | 569.7 | 402.5 | |
| DR. REDDYS LAB INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 134,153 | 150,233 | 155,683 | 141,961 | 142,810 | |
| Other income | Rs m | 1,697 | 2,741 | 2,950 | 1,715 | 1,552 | |
| Total revenues | Rs m | 135,850 | 152,974 | 158,633 | 143,676 | 144,362 | |
| Gross profit | Rs m | 32,508 | 34,936 | 35,853 | 24,722 | 23,512 | |
| Depreciation | Rs m | 6,475 | 7,599 | 9,389 | 10,266 | 10,772 | |
| Interest | Rs m | 1,267 | 1,082 | 826 | 634 | 788 | |
| Profit before tax | Rs m | 26,463 | 28,996 | 28,588 | 15,537 | 13,504 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 229 | 349 | 344 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 6,831 | 5,632 | 7,511 | 2,965 | 4,380 | |
| Profit after tax | Rs m | 19,632 | 23,364 | 21,306 | 12,921 | 9,468 | |
| Gross profit margin | % | 24.2 | 23.3 | 23.0 | 17.4 | 16.5 | |
| Effective tax rate | % | 25.8 | 19.4 | 26.3 | 19.1 | 32.4 | |
| Net profit margin | % | 14.6 | 15.6 | 13.7 | 9.1 | 6.6 | |
| DR. REDDYS LAB BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 103,257 | 118,096 | 117,940 | 96,837 | 104,984 | |
| Current liabilities | Rs m | 57,904 | 63,734 | 63,471 | 84,199 | 68,938 | |
| Net working cap to sales | % | 33.8 | 36.2 | 35.0 | 8.9 | 25.2 | |
| Current ratio | x | 1.8 | 1.9 | 1.9 | 1.2 | 1.5 | |
| Inventory Days | Days | 66 | 62 | 60 | 73 | 74 | |
| Debtors Days | Days | 90 | 99 | 97 | 98 | 104 | |
| Net fixed assets | Rs m | 52,796 | 59,065 | 73,352 | 102,552 | 104,385 | |
| Share capital | Rs m | 851 | 852 | 853 | 829 | 830 | |
| "Free" reserves | Rs m | 72,946 | 107,482 | 124,845 | 121,792 | 124,886 | |
| Net worth | Rs m | 78,652 | 108,334 | 125,698 | 122,621 | 125,716 | |
| Long term debt | Rs m | 20,755 | 14,307 | 10,685 | 5,449 | 25,089 | |
| Total assets | Rs m | 160,296 | 190,650 | 203,841 | 218,165 | 225,443 | |
| Interest coverage | x | 21.9 | 27.8 | 35.6 | 25.5 | 18.1 | |
| Debt to equity ratio | x | 0.3 | 0.1 | 0.1 | 0 | 0.2 | |
| Sales to assets ratio | x | 0.8 | 0.8 | 0.8 | 0.7 | 0.6 | |
| Return on assets | % | 13.0 | 12.8 | 10.9 | 6.2 | 4.5 | |
| Return on equity | % | 25.0 | 21.6 | 17.0 | 10.5 | 7.5 | |
| Return on capital | % | 27.9 | 24.5 | 21.7 | 12.9 | 9.7 | |
| Exports to sales | % | 55.2 | 49.4 | 46.6 | 54.6 | 0 | |
| Imports to sales | % | 8.9 | 9.0 | 9.0 | 9.4 | 0 | |
| Exports (fob) | Rs m | 74,059 | 74,146 | 72,618 | 77,520 | 0 | |
| Imports (cif) | Rs m | 11,959 | 13,485 | 14,050 | 13,274 | 0 | |
| Fx inflow | Rs m | 76,007 | 74,870 | 75,405 | 81,670 | 72,623 | |
| Fx outflow | Rs m | 24,607 | 26,008 | 27,115 | 26,355 | 18,916 | |
| Net fx | Rs m | 51,400 | 48,862 | 48,290 | 55,315 | 53,707 | |
| DR. REDDYS LAB CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 19,697 | 25,235 | 32,626 | 21,444 | 18,030 | |
| From Investments | Rs m | -16,941 | -22,647 | -20,394 | -18,404 | -14,883 | |
| From Financial Activity | Rs m | -242 | -4,332 | -17,001 | -3,692 | -4,440 | |
| Net Cashflow | Rs m | 2,514 | -1,744 | -474 | -1,144 | -1,236 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: G. V. Prasad | COMP SEC: Sandeep Poddar | YEAR OF INC: 1984 | BSE CODE: 500124 | FV (Rs): 5 | DIV YIELD (%): 0.8 |
More Pharmaceuticals Company Fact Sheets: CIPLA AUROBINDO PHARMA VENUS REMEDIES FRESENIUS KABI ONCO. ASTRAZENECA PHARMA
Compare DR. REDDYS LAB With: CIPLA AUROBINDO PHARMA VENUS REMEDIES FRESENIUS KABI ONCO. ASTRAZENECA PHARMA
Compare DR. REDDYS LAB With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 134 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)
Indian share markets witnessed selling pressure throughout the day and ended marginally lower. Sectoral indices ended on a mixed note with stocks.
Views on news
DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)
Jul 27, 2018 | Updated on Jul 27, 2018For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)
Nov 13, 2017Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
More Views on NewsMost Popular
Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)
Jan 9, 2019For the first time, we have recommended a bluechip stock in Smart Money Secrets.
3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)
Jan 11, 2019The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling
This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)
Jan 15, 2019Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.
My First Stock Trading Recommendation For 2019(Profit Hunter)
Jan 10, 2019My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.
My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)
Jan 14, 2019With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.
More|
| |
TRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB 8-QTR ANALYSIS
COMPARE DR. REDDYS LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.